Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: A luminescent cerium (Ce) doped compound emitting bright red light, comprising a calcium silicate nitride ternary system, such as CaSiN2-?O?:Ce3+, that crystallizes in a face-centered cubic unit cell with a lattice parameter of ˜a=14.88 ?. The Ce doped compound can be used for white light applications either: (i) to enhance the light quality of the system based on a blue LED with a yellow or green phosphor, (ii) as an orange phosphor in combination with a blue LED and a green phosphor, or (iii) as a red phosphor in a setup comprising a ultraviolet (UV) LED and red, green and blue (RGB) phosphors. Substitution of smaller elements on the Ca site or larger elements on the Si site leads to a decrease of the emission wavelength towards the yellow or orange region.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: A crystalline phosphor of formula: Lnx.(1?t1?t2?t3?t4)Ybx.t1Erx.t2Tmx.t3Hox.14BayZnzO1.5x+y+z in which: Ln is Y, Gd or La; t1+t2+t3+t4 varies from 0.001 to 0.3; and such that, when x=2, y=1 and z=1: t1+t3+t4 is nonzero; if Ln is La or Gd and if t3+t4 is zero, then t1 varies from 0.05 to 0.1 and t2 varies from 0.02 to 0.07; and if Ln is Gd, then t2+t4 is nonzero.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: Methods for improving ejaculate of a patient in need thereof are presented, more particularly, methods for increasing ejaculate volume/prostatic fluid to increase viability of sperm contained therein by administration of a neurotoxin to the prostate of the patient, are provided.

Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

Abstract: The subject of the invention is a compound chosen from compounds of formula Y2BaZnO5:Er3+, La2BaZnO5:Er3+, Gd2BaZnO5:Er3+, Gd2BaZnO5:Yb3+/Er3+, Gd2BaZnO5:Yb3+/Tm3+. These compounds are capable of converting radiation into radiation with a higher energy level than that of the incident radiation.

Abstract: A titration package and method for enabling compliance with a regimen of changing dosage of medication over a period of time includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows. A plurality of sets of Memantine tablets are provided with each tablet set having a common dose of medication and a different does than a tablet of a different set. Each set of tablets is disposed in receivers of one having an adjacent row and an adjacent column. Indicia is provided and disposed adjacent to the columns and rows for displaying common days and successive weeks.

Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.

Abstract: The present invention relates to a process for preparing nanoporous VSB-5 molecular sieves, and more particularly, to a process for preparing nanoporous VSB-5 molecular sieves useful as a hydrogen storage material, a catalyst, a catalyst supporter and an adsorbent, performed in such a manner that low-cost inorganic base or monoamine instead of a template essential in the conventional process is, as a pH modifier, incorporated into raw materials comprised of nickel and phosphorous compounds and crystallized to give VSB-5 molecular sieves in an economical and efficient manner.

Abstract: The present invention relates to a composition of metal-incorporated VSB-5 molecular sieve with nanopores and its preparation method, in particular, to a composition of a metal-incorporated VSB-5 molecular sieve with a framework of VSB-5 molecular sieve comprising nickel, phosphorous, oxygen and metal, which is useful in various fields such as a hydrogen storage material, an optical and electric/electronic material, a sensor, a catalyst, a catalyst supporter and an adsorbent, and its preparation method performed in such a manner that a specific metal component is added in a predetermined mole ratio to a reaction mixture comprised of nickel and phosphorous compounds and the resultant mixture is crystallized in the presence of inorganic or organic base as a pH modifier to yield a metal-incorporated VSB-5 molecular sieves in an economical and efficient manner.

Abstract: A red phosphor composition in combination with a semiconductor light emitting device (e.g., VCSEL, LED, or LD), preferably a GaN based device, that emits light at a bright violet-blue light range, i.e., having a wavelength in the range of 400 nm to 600 nm, which can be further combined with green and blue phosphors. The red phosphor composition in the combination is a vanadate combined with yttrium, gadolinium and/or lanthanum and activated with trivalent Eu3+, Sm3+ and Pr330 , or any combination thereof, with or without Tb3+ as a co-dopant, has the general formula: BixLn1-xVO4:A where x=0 to 1, Ln is an element selected from the group consisting of Y, La and Gd, and A is an activator selected from Eu3+, Sm3+ and Pr3+, or any combination thereof, with or without Tb3+ as a co-dopant. Novel red phosphor compositions are provided when x is greater than 0 and less than 1, preferably 0.05 to 0.5.